CALGARY, Jan. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (“Oncolytics”) announced today the appointment of Mary Ann Dillahunty as Vice President, Intellectual Property.
“Ms. Dillahunty possesses a unique combination of experience in the biopharmaceutical industry spanning several decades and ranging from patent portfolio development and prosecution to regulatory affairs consulting, business development and research science,” said Dr. Brad Thompson, President and CEO of Oncolytics. “In addition, she has been involved with the development of Oncolytics’ intellectual property portfolio since 1999 in her role as Oncolytics’ external patent counsel. As part of our management team, Ms. Dillahunty is expected to maximize Oncolytics’ patent potential for REOLYSIN(R), while offering senior level counsel to the Company on its strategic development.”
Prior to joining Oncolytics, Ms. Dillahunty was a principal in the law firm of Fish & Richardson, a leading intellectual property firm in the U.S. In 1992, she joined the law firm of Burns, Doane, Swecker & Mathis (now part of Buchanan Ingersoll & Rooney), and subsequently became a partner in the firm. During 1996-1997, Ms. Dillahunty held the position of patent counsel to the Implant Division of ALZA Corporation. Before joining Burns Doane, she was a patent agent and law clerk with the law firm of Heller, Ehrman, White & McAuliffe. Prior to focusing her career on patent law, Ms. Dillahunty held numerous positions in the biotechnology, pharmaceutical and medical device industries, including responsibilities in regulatory affairs and research science. Ms. Dillahunty holds a B.S. in Microbiology from Michigan State University, an MBA from George Washington University, and a JD degree from Stanford Law School.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the impact Ms. Dillahunty will have on the development of the Company’s intellectual property and strategic development and the Company’s belief as to the potential of REOLYSIN(R) as a cancer therapeutic, alone, or in combination with other therapies, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.
Oncolytics Biotech Inc.
CONTACT: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW,Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,cathy.ward@oncolytics.ca; The Equicom Group, Nick Hurst, 600, 205 5th Ave.SW, Calgary, Alberta, T2P 2V7, Tel: (403) 538-4845, Fax: (403) 266-2453,nhurst@equicomgroup.com; The Investor Relations Group, Erika Moran, 11Stone St, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212)825-3229, emoran@investorrelationsgroup.com
